GC
ANIP icon

Guggenheim Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Guggenheim Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$790K Buy
+9,540
New +$765K 0.01% 1111
2026
Q1 		– Sell
-16,845
Closed -$1.33M – 1607
2025
Q4 		$1.33M Buy
+16,845
New +$1.46M 0.01% 801
2020
Q1 		– Sell
-4,415
Closed -$272K – 1844
2019
Q4 		$272K Buy
+4,415
New +$292K ﹤0.01% 1873
2018
Q4 		– Sell
-6,082
Closed -$344K – 2172
2018
Q3 		$344K Buy
6,082
+1,157
+23% +$70.8K ﹤0.01% 2161
2018
Q2 		$329K Sell
4,925
-38,965
-89% -$2.43M ﹤0.01% 2153
2018
Q1 		$2.56M Buy
43,890
+199
+0.5% +$12.6K 0.01% 1462
2017
Q4 		$2.82M Sell
43,691
-8,675
-17% -$540K 0.01% 1406
2017
Q3 		$2.75M Sell
52,366
-23
-0% -$1.1K 0.01% 1444
2017
Q2 		$2.45M Sell
52,389
-2,899
-5% -$140K 0.01% 1491
2017
Q1 		$2.74M Buy
55,288
+3,873
+8% +$217K 0.01% 1420
2016
Q4 		$3.12M Buy
51,415
+31,935
+164% +$1.95M 0.01% 1322
2016
Q3 		$1.29M Sell
19,480
-2,114
-10% -$132K ﹤0.01% 1919
2016
Q2 		$1.21M Buy
+21,594
New +$1.05M ﹤0.01% 1920
2016
Q1 		– Sell
-26,198
Closed -$1.18M – 2909
2015
Q4 		$1.18M Buy
+26,198
New +$1.13M ﹤0.01% 1999
2014
Q3 		– Sell
-65,222
Closed -$2.25M – 2995
2014
Q2 		$2.25M Buy
+65,222
New +$2.05M 0.01% 1708
2013
Q3 		– Sell
-3,761
Closed -$23K – 3064
2013
Q2 		$23K Buy
+3,761
New +$26.3K ﹤0.01% 2978

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Guggenheim Capital's ANIP Position: Q2 2026 in Review

Guggenheim Capital opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 9,540 shares worth $790K. The stake represents 0.01% of the portfolio and ranks #1111 among its holdings. This is a return to the name: Guggenheim Capital previously reported a position in ANIP as recently as Q4 2025.

Guggenheim Capital first reported a position in ANIP in Q2 2013 and has held it in 16 quarters since. The position peaked at $3.12M in Q4 2016. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Guggenheim Capital held 9,540 shares of ANI Pharmaceuticals worth $790K as of Q2 2026.
  • ANI Pharmaceuticals was a new Guggenheim Capital position in Q2 2026.
  • ANI Pharmaceuticals made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1111 holding.
  • Guggenheim Capital first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
  • Guggenheim Capital's ANI Pharmaceuticals position peaked at $3.12M in Q4 2016.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.